Anti Ageing Gene Therapy is making headlines after the world’s first human trial began in the United States. Scientists have injected an experimental gene treatment into a patient’s eye to study whether it can reverse ageing in cells and restore vision. The breakthrough has created excitement in the medical and longevity research world.
The treatment, called ER-100, was developed by Life Biosciences in Boston. It uses partial cellular reprogramming, a process that helps old cells behave like younger cells again. Researchers say the therapy may help patients suffering from glaucoma and optic nerve damage. The Anti Ageing Gene Therapy works by changing how genes are read inside the body without changing DNA itself.
Doctors chose the eye for the first human test because it is safer and easier to monitor. Patients receive one injection into the eye and later take antibiotics that activate special therapeutic genes. The main goal of the Phase 1 trial is to check safety and possible side effects.
The science behind this treatment comes from Nobel Prize-winning research by Japanese scientist Shinya Yamanaka. His discovery showed that certain genes can reset ageing cells. Scientists now use a safer method called partial reprogramming to avoid dangerous risks.
The trial has also gained attention because of interest from famous longevity researchers and tech billionaire Elon Musk. Experts still warn that more testing is needed because changing gene activity may increase cancer risks.
Even so, this Anti Ageing Gene Therapy marks an important step in medical science. Researchers hope it could one day help slow ageing and treat serious diseases linked to growing old.
